✦ LIBER ✦

Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

✍ Scribed by Johnson, J. R.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A cross-market cost comparison of erloti

✍ Nuijten, Mark J.C.; de Castro Carpeño, Javier; Chouaid, Christos; Vergnenègre, A 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 375 KB

Phase II study of erlotinib for chemothe

✍ Dae Ho Lee; Sang-We Kim; Cheolwon Suh; Yun Hee Han; Jung-Shin Lee 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 241 KB

Afatinib versus placebo for patients wit

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB

PCN43 COST COMPARISON OF ERLOTINIB VERSU

✍ S Ravera; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN44 COST COMPARISON OF ERLOTINIB VERSU

✍ J Castro de Carpeño; AJ Castro-Gómez; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

26 Audit of gefitinib for the first-line

✍ Douglas, R.; Campbell, L.; McAleese, J.; Scullin, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB